Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Sees Significant Decrease in Short Interest

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the recipient of a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 12,494 shares, a drop of 54.0% from the February 12th total of 27,138 shares. Based on an average daily trading volume, of 78 shares, the short-interest ratio is currently 160.2 days. Based on an average daily trading volume, of 78 shares, the short-interest ratio is currently 160.2 days.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday, February 12th. Wedbush started coverage on shares of Hansa Biopharma AB (publ) in a report on Wednesday, January 7th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hansa Biopharma AB (publ) currently has an average rating of “Buy”.

Hansa Biopharma AB (publ) Price Performance

Hansa Biopharma AB (publ) stock opened at $2.90 on Friday. The firm has a fifty day moving average of $2.91 and a 200-day moving average of $3.21. Hansa Biopharma AB has a 52-week low of $2.73 and a 52-week high of $4.58.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.